21
David S Garvey, Inigo Saenz de Tejada, Richard A Earl, Subhash P Khanapure: Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use. NitroMed, Hale and Dorr, December 18, 2001: US06331543 (41 worldwide citation)

The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate ...


22
Thomas Julius Borody, Walter George Shortis, Nicolas Peter Shortis: Picosulfate-containing preparation for colonic evacuation. January 12, 1999: US05858403 (41 worldwide citation)

An osmotic colonic evacuant in solid dosage form, which comprises a phosphate based laxative or a sulfate based laxative and preferably comprises sodium picosulfate and an antacid, is used preferably in conjunction with 250 ml to 1,500 ml diluent, alone or as part of a sequential pack, to evacuate t ...


23
Hulin Bernard: Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides. Pfizer Products, Hulin Bernard, LUMB J Trevor, June 3, 2004: WO/2004/046106 (41 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, suc ...


24
Hulin Bernard, Parker Janice C: Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors. Pfizer Products, Hulin Bernard, Parker Janice C, FULLER Grover F Jr, March 3, 2005: WO/2005/019168 (40 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV ('DPP-IV')of formula (Ia) and (Ib), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are s ...


25
Ernst Glen, Phillips Eifion, Schmiesing Richard: Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016617 (40 worldwide citation)

Nicotinic acetylcholine receptor of formula (I) wherein D, Ar1, E and Ar2 are as defined in the specification, enantiomers, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic disorde ...


26
Jean Michel Vernier, Nicholas D P Cosford, Ian A McDonald: Substituted pyridine compounds useful as modulators of acetylcholine receptors. Merck & Co, David Rubin, David L Rose, October 14, 2003: US06632823 (39 worldwide citation)

In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the pre ...


27
John L Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Bennett Jones, March 22, 2011: US07910568 (39 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...


28
Ernst Glen, Phillips Eifion, Schmiesing Richard: Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016616 (37 worldwide citation)

Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically- acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic ...


29
William Dennis Allen, Margaret Anneli Linggood, Philip Porter: Priobiotic containing enterococcus faecium strain NCIMB 40371. Unilever Patent Holdings, Cushman Darby & Cushman IP Group Pillsbury Madison & Sutro, March 17, 1998: US05728380 (36 worldwide citation)

A strain of Enterococcus faecium, deposited as NCIMB 40371, has valuable probiotic properties and is particularly effective in alleviating symptoms of irritable bowel syndrome (IBS) in human patients. The strain can be used in the manufacture of human foodstuffs.


30
John Rhodes, Brian Kenneth Evans: Composition for treatment of constipation and irritable bowel syndrome. John Rhodes, Brian Kenneth Evans, Birch Stewart Kolasch & Birch, May 11, 2004: US06734188 (36 worldwide citation)

Constipation and Irritable Bowel Syndrome are treated by a delayed and sustained release composition of an opioid antagonist which commences release of the opioid antagonist in the mid to distal small intestine or ascending colon and provides sustained release along any remaining part of the small i ...



Click the thumbnails below to visualize the patent trend.